(FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome
Key facts
- Who runs it
- Zagazig University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 183 people enrolled
- Started
- 1 Jun 2024
- Ended
- 30 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Low Fermentable, Oligo-, Di-, Monosaccharides and Polyols (FODMAP) Diet
- Record updated
- 23 December 2025
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- newly diagnosed with IBS based on Rome IV criteria and subtypes of IBS included constipation-predominant, diarrhea predominant, mixed, and unspecified,
- aged 18 to 60 years old of both genders,
- after taking their consent to participate
Who cannot take part
- Patients who previously diagnosed with GI comorbidities (such as inflammatory bowel disease, celiac disease, lactose malabsorption, significant diverticular disease, or a history of bowel resection)
- drug abuse
- Clinically significant systemic disease
- serious psychiatric diseases
- eating disorders
- pregnant or lactating
- Presence of blood or pus in stool analysis
- Individuals with IBS-alarming symptoms as (did not have a normal colonoscopy)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction, characterized by chronic abdominal pain and altered bowel habits. A low-FODMAP diet (LFD), which restricts specific types of fermentable carbohydrates, significantly reduces IBS symptoms and improves quality of life (QoL). Objectives: To evaluate the short- and long-term effects of LFD on improving symptom severity and the quality of life of IBS patients attending the family medicine outpatient clinic, and to assess LFD acceptability and adherence of IBS patients. Methods: Randomized control trial conducted on (123 patients) with IBS attending outpatient clinic of family medicine at Tenth of Ramadan University Hospital from 1st of June 2024 to the end of June 2025. An intervention group (No=93) received patient-centered education about LFD, and a control group (No.=90). Participants in both groups underwent an assessment of their BMI, Irritable Bowel Syndrome- Severity Scoring System (IBS-SSS), and irritable bowel syndrome-Quality of Life Measure (IBS-QOL) preintervention during the first visit and reassessed post-intervention after one, three, and six months. Additionally, Patients in the intervention group were assessed for the FODMAP Adherence Report Scale (FARS), LFD acceptability questionnaire, and Food-related QOL questionnaire at one, three-, and six-month post-intervention phases.
The 2 groups in the trial
- Intervention groupTreatment being tested
follow low fermentable- oligo-Di- monosaccharides and polyols(FODMPD) diet as intervention program
Treatment: Low Fermentable, Oligo-, Di-, Monosaccharides and Polyols (FODMAP) Diet
- Control groupNo study treatment, for comparison
control group were patients with irritable bowel syndrome don't follow any intervention program
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Low Fermentable, Oligo-, di-, Monosaccharides and Polyols (FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome (Randomized Control Trial)
- Record updated
- 23 December 2025